Bausch Health (BHC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting is scheduled for October 7, 2025, to ratify and approve the Amended and Restated Shareholder Rights Plan.
The Rights Plan aims to ensure fair treatment of all shareholders in the event of unsolicited take-over bids or acquisitions of control.
The Board recommends voting in favor of the Rights Plan, which aligns with Canadian corporate governance best practices.
The Rights Plan is not intended to prevent take-overs but to encourage fair and equal treatment and negotiation.
Voting matters and shareholder proposals
Shareholders will vote on an ordinary resolution to ratify, confirm, and approve the Amended and Restated Shareholder Rights Plan.
Approval requires a simple majority of votes cast by all shareholders, excluding any Grandfathered Persons and only Independent Shareholders.
No other matters are currently expected to be brought before the meeting.
Board of directors and corporate governance
The Board unanimously supports the Rights Plan and believes it is in the best interests of the company and shareholders.
Shareholders can communicate directly with the Board or independent directors via mail, email, or a dedicated helpline.
Latest events from Bausch Health
- 11th straight quarter of revenue and EBITDA growth, with strong segment results and lower net debt.BHC
Q4 202520 Feb 2026 - Q2 2024 revenue up 11% to $2.40B, adjusted EBITDA up 10%, and debt reduced by $360M.BHC
Q2 20242 Feb 2026 - Q3 revenue up 12%, Adjusted EBITDA up 10%, guidance raised, and all segments grew.BHC
Q3 202417 Jan 2026 - Strong 2024 results and 2025 growth outlook driven by GI, aesthetics, and neuroscience franchises.BHC
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Full-year revenue and adjusted EBITDA rose 10%, with all segments contributing to growth.BHC
Q4 202429 Dec 2025 - Q1 2025 revenue up 5% to $2.26B; $7.9B refinancing extends debt maturities and boosts flexibility.BHC
Q1 202522 Dec 2025 - Growth in GI, Solta, and international markets, with XIFAXAN exclusivity and trial data as key focus.BHC
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025 - Board recommends approval of all annual meeting proposals, with strong governance and ESG focus.BHC
Proxy Filing2 Dec 2025 - Shareholders will vote on ratifying a Rights Plan to ensure fair treatment in take-over bids.BHC
Proxy Filing2 Dec 2025